A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease

被引:17
|
作者
Noor, Neveen A. [1 ]
Mohammed, Haitham S. [2 ]
Mourad, Iman M. [1 ]
Khadrawy, Yasser A. [3 ]
Ezz, Heba S. Aboul [1 ]
机构
[1] Cairo Univ, Fac Sci, Dept Zool, Giza, Egypt
[2] Cairo Univ, Fac Sci, Dept Biophys, Giza, Egypt
[3] Natl Res Ctr, Dept Med Physiol, Div Med, Cairo, Egypt
关键词
Parkinson's disease; Cerebrolysin; 6-hydroxydopamine; Rat; Substantia nigra; OXIDATIVE STRESS; LIPID-PEROXIDATION; ANIMAL-MODELS; BRAIN-INJURY; DOPAMINE; LIPOPOLYSACCHARIDE; NEUROTOXICITY; MECHANISMS; PATHWAYS; NITRITE;
D O I
10.1016/j.lfs.2016.05.022
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aims: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease affecting the population. The present study investigates the potential therapeutic effect of cerebrolysin (CBL), as a neurotrophic factor mimic, on the behavioral and biochemical alterations induced in 6-hydroxydopamine (6-OHDA) -lesioned rats as a model of PD. Main methods: The animals were divided into 3 experimental groups; control group, Parkinsonian model group through bilateral microinjection of 6-OHDA into substantia nigra (SN) and CBL-treated group which received a daily intraperitoneal administration of CBL (2.5 ml/kg) initiated 24 h after induction of Parkinsonism for 21 days. Key findings: Treatment of Parkinsonian animals with CBL succeeded in restoring the midbrain and striatum dopamine levels. In addition, it normalized the increased MDA and NO levels recorded in the Parkinsonian animals and replenished the decreased level of midbrain GSH. In addition to the recorded recovery of the biochemical parameters, there was a parallel improvement in the animal's behavioral aspects. Significance: The findings of the present study provide evidence for the promising therapeutic effect of CBL in the present 6-OHDA rat model of PD through counteracting oxidative stress, replenishing dopamine content and enhancing behavioral outcomes. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 50 条
  • [1] Probucol Affords Neuroprotection in a 6-OHDA Mouse Model of Parkinson's Disease
    Ribeiro, Renata Pietsch
    Gasnhar Moreira, Eduardo Luiz
    Santos, Danubia Bonfanti
    Colle, Dirleise
    dos Santos, Alessandra Antunes
    Peres, Kaite Cristiane
    Figueiredo, Claudia Pinto
    Farina, Marcelo
    NEUROCHEMICAL RESEARCH, 2013, 38 (03) : 660 - 668
  • [2] Effect of 6-OHDA on Hypercapnic Ventilatory Response in the Rat Model of Parkinson's Disease
    Andrzejewski, K.
    Budzinska, K.
    Kaczynska, K.
    PHYSIOLOGICAL RESEARCH, 2019, 68 (02) : 285 - 293
  • [3] Functional neuroimaging of the 6-OHDA lesion rat model of Parkinson's disease
    Jang, Dong Pyo
    Min, Hoon-Ki
    Lee, Sang-Yoon
    Kim, In Young
    Park, Hyung Woo
    Im, Yong Hoon
    Lee, Sohee
    Sim, Jeongeun
    Kim, Young-Bo
    Paek, Sun Ha
    Cho, Zang-Hee
    NEUROSCIENCE LETTERS, 2012, 513 (02) : 187 - 192
  • [4] Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA
    Chan, Hugh H. N.
    Kumar, Saravana
    Zhuo, Lang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 715 (1-3) : 405 - 413
  • [5] Triptolide Protects Dopaminergic Neurons from 6-OHDA Lesion in a Rat Model of Parkinson's Disease
    Zhang, Wenjing
    An, Haiting
    Zhang, Feilong
    Dong, Lin
    Wang, Qi
    Su, Ruijun
    Qian, Yanjing
    Gong, Xiaoli
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2015, 11 (01) : 10 - 18
  • [6] Neuroprotective effect and mechanism of baicalin on Parkinson's disease model induced by 6-OHDA
    Tu, Li
    Wu, Zhuo-Yu
    Yang, Xiu-Lin
    Zhang, Qian
    Gu, Ran
    Wang, Qian
    Tian, Tian
    Yao, Huan
    Qu, Xiang
    Tian, Jin-Yong
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 3615 - 3625
  • [7] Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson's disease
    Fine, J. M.
    Forsberg, A. C.
    Renner, D. B.
    Faltesek, K. A.
    Mohan, K. G.
    Wong, J. C.
    Arneson, L. C.
    Crow, J. M.
    Frey, W. H., II
    Hanson, L. R.
    BRAIN RESEARCH, 2014, 1574 : 96 - 104
  • [8] Probucol Affords Neuroprotection in a 6-OHDA Mouse Model of Parkinson’s Disease
    Renata Pietsch Ribeiro
    Eduardo Luiz Gasnhar Moreira
    Danúbia Bonfanti Santos
    Dirleise Colle
    Alessandra Antunes dos Santos
    Kaite Cristiane Peres
    Claudia Pinto Figueiredo
    Marcelo Farina
    Neurochemical Research, 2013, 38 : 660 - 668
  • [9] Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine
    Tharwat, Engy K. K.
    Abdelaty, Ahmed O. O.
    Abdelrahman, Alaa I. I.
    Elsaeed, Hebatallah
    Elgohary, Ayatallah
    El-Feky, Amena S. S.
    Ebrahim, Yasmina M. M.
    Sakraan, Alaa
    Ismail, Hossam A. A.
    Khadrawy, Yasser A. A.
    Aboul Ezz, Heba S. S.
    Noor, Neveen A. A.
    Fahmy, Heba M. M.
    Mohammed, Haitham S. S.
    Mohammed, Faten F. F.
    Radwan, Nasr M. M.
    Ahmed, Nawal A. A.
    METABOLIC BRAIN DISEASE, 2023, 38 (05) : 1513 - 1529
  • [10] Propolis as a Potential Disease-Modifying Strategy in Parkinson's disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model
    Goncalves, Valeria C.
    Pinheiro, Daniel J. L. L.
    de la Rosa, Tomas
    de Almeida, Antonio-Carlos G.
    Scorza, Fulvio A.
    Scorza, Carla A.
    NUTRIENTS, 2020, 12 (06)